EP2804600A4 - Procédés et formulations permettant de traiter les déficiences en acide sialique - Google Patents

Procédés et formulations permettant de traiter les déficiences en acide sialique

Info

Publication number
EP2804600A4
EP2804600A4 EP13739040.7A EP13739040A EP2804600A4 EP 2804600 A4 EP2804600 A4 EP 2804600A4 EP 13739040 A EP13739040 A EP 13739040A EP 2804600 A4 EP2804600 A4 EP 2804600A4
Authority
EP
European Patent Office
Prior art keywords
formulations
methods
sialic acid
acid deficiencies
treating sialic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13739040.7A
Other languages
German (de)
English (en)
Other versions
EP2804600A2 (fr
Inventor
Emil D Kakkis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultragenyx Pharmaceutical Inc
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of EP2804600A2 publication Critical patent/EP2804600A2/fr
Publication of EP2804600A4 publication Critical patent/EP2804600A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP13739040.7A 2012-01-18 2013-01-18 Procédés et formulations permettant de traiter les déficiences en acide sialique Withdrawn EP2804600A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261588069P 2012-01-18 2012-01-18
US201261709549P 2012-10-04 2012-10-04
PCT/US2013/022167 WO2013109906A2 (fr) 2012-01-18 2013-01-18 Procédés et formulations permettant de traiter les déficiences en acide sialique

Publications (2)

Publication Number Publication Date
EP2804600A2 EP2804600A2 (fr) 2014-11-26
EP2804600A4 true EP2804600A4 (fr) 2015-09-02

Family

ID=48799814

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13739040.7A Withdrawn EP2804600A4 (fr) 2012-01-18 2013-01-18 Procédés et formulations permettant de traiter les déficiences en acide sialique

Country Status (9)

Country Link
EP (1) EP2804600A4 (fr)
JP (2) JP2015504094A (fr)
KR (1) KR20150000872A (fr)
CN (1) CN104271125A (fr)
AU (1) AU2013209610B2 (fr)
BR (1) BR112014017587A8 (fr)
CA (1) CA2862836A1 (fr)
IL (1) IL233225A0 (fr)
WO (1) WO2013109906A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
AU2011279158B2 (en) 2010-07-13 2015-07-09 Ultragenyx Pharmaceutical Inc. Method and formulations for treating sialic acid deficiencies
KR102049214B1 (ko) 2011-10-24 2019-11-28 울트라제닉스 파마수티컬 인코포레이티드 시알산 유사체
WO2017048817A1 (fr) 2015-09-14 2017-03-23 Ultragenyx Pharmaceutical Inc. Formes cristallines d'acide sialique ou sel ou solvate de celles-ci
EP3486326A1 (fr) 2017-11-21 2019-05-22 Jennewein Biotechnologie GmbH Procédé de purification d'acide n-acétylneuraminique à partir d'un bouillon de fermentation
CN117969774B (zh) * 2024-04-02 2024-06-11 小仙炖霸州食品有限公司 一种自动化燕窝检测与分级系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150477A2 (fr) * 2007-05-31 2008-12-11 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Mannosamine de n-acétyle en tant qu'agent thérapeutique
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
WO2010131712A1 (fr) * 2009-05-15 2010-11-18 財団法人ヒューマンサイエンス振興財団 Agent pharmaceutique destine au traitement des maladies associees a une diminution de la fonction de la proteine gne, composition et additif alimentaires
WO2012009474A1 (fr) * 2010-07-13 2012-01-19 Ultragenyx Pharmaceutical Inc. Méthode et formulations destinées au traitement de déficiences en acide sialique
WO2013063149A1 (fr) * 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Analogues de l'acide sialique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150477A2 (fr) * 2007-05-31 2008-12-11 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Mannosamine de n-acétyle en tant qu'agent thérapeutique
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
WO2010131712A1 (fr) * 2009-05-15 2010-11-18 財団法人ヒューマンサイエンス振興財団 Agent pharmaceutique destine au traitement des maladies associees a une diminution de la fonction de la proteine gne, composition et additif alimentaires
US20120264928A1 (en) * 2009-05-15 2012-10-18 Japan Health Sciences Foundation Therapeutic pharmaceutical agent for diseases associated with decrease in function of gne protein, food composition, and food additive
WO2012009474A1 (fr) * 2010-07-13 2012-01-19 Ultragenyx Pharmaceutical Inc. Méthode et formulations destinées au traitement de déficiences en acide sialique
WO2013063149A1 (fr) * 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Analogues de l'acide sialique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAY CHRISTINE V MALICDAN ET AL: "Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model", NATURE MEDICINE, vol. 15, no. 6, 1 June 2009 (2009-06-01), pages 690 - 695, XP055175431, ISSN: 1078-8956, DOI: 10.1038/nm.1956 *

Also Published As

Publication number Publication date
AU2013209610B2 (en) 2017-11-30
BR112014017587A2 (pt) 2017-06-13
KR20150000872A (ko) 2015-01-05
EP2804600A2 (fr) 2014-11-26
JP2015504094A (ja) 2015-02-05
JP2017186381A (ja) 2017-10-12
BR112014017587A8 (pt) 2017-07-04
AU2013209610A1 (en) 2014-07-10
IL233225A0 (en) 2014-08-31
WO2013109906A2 (fr) 2013-07-25
CA2862836A1 (fr) 2013-07-25
CN104271125A (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
IL235826A (en) Diazaspirocycloalkanes and thenaspirocycloalkanes and their preparation
HK1209745A1 (en) Compounds and methods for antiviral treatment
HK1201475A1 (en) Methods and compositions for treating pain
EP2684167A4 (fr) Compositions et méthodes utiles dans le traitement de maladies
HK1203830A1 (en) Compositions and methods for treating metabolic disorders
IL269166A (en) Methods and preparations for treating inflammation
EP2593109A4 (fr) Méthode et formulations destinées au traitement de déficiences en acide sialique
DK3292875T3 (en) Compositions and methods for treating diseases
EP2691529A4 (fr) Procédés et compositions pour traiter des maladies cérébrales
IL233225A0 (en) Methods and formulations for the treatment of sialic acid deficiencies
EP2806894A4 (fr) Procédés et compositions pour agents thérapeutiques
HK1208598A1 (en) Methods and compositions for treating pain
IL235805A (en) Pyrimidinyl-Diazaspiro compound and process for preparation
EP2863939A4 (fr) Compositions et procédés pour le traitement du vitiligo
EP2928460A4 (fr) Procédés pour la prévention et le traitement d'affections cutanées inflammatoires
HK1209040A1 (en) Methods for treating vestibulotoxicity
EP2714082A4 (fr) Compositions et méthodes de traitement de la douleur
GB201100455D0 (en) Methods relating to treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140711

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150804

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 21/00 20060101ALI20150729BHEP

Ipc: A61K 9/20 20060101ALI20150729BHEP

Ipc: A61K 9/22 20060101ALI20150729BHEP

Ipc: A61K 31/7012 20060101AFI20150729BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20180112